M&A / Deals MSD concludes Terns acquisition to expand CML pipeline Pharmaceutical TechnologyMSD has completed its acquisition of Terns Pharmaceuticals, expanding its pipeline of treatments for chronic myeloid leukaemia (CML).HematologyRead full story pharminent May 6, 2026 (Last updated: May 6, 2026) Pharmaceutical Technology MSD has completed its acquisition of Terns Pharmaceuticals, expanding its pipeline of treatments for chronic myeloid leukaemia (CML). Hematology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA Expands Market Access, Authorizes New ENDS ProductsNext: MSD concludes Terns acquisition to expand CML pipeline Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
